Bronchiectasis-Associated Hospitalizations in Germany, 2005 – 2011: A Population-Based Study of Disease Burden and Trends

Ringshausen, FC; Roux, A de; Pletz, MW; Hamalainen, N.; Welte, Tobias; Rademacher, Jessica

doi:10.1055/s-0034-1376839

Cited by 18 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increasing trend in the health burden of CSLD and bronchiectasis is recognised in both Indigenous and non‐Indigenous settings in Australia, New Zealand and worldwide 3 , 5 . ‐ 7 Some affluent countries report childhood fatalities, 7 and there is a growing appreciation of the economic cost 5 . Misdiagnosis or coexistence of bronchiectasis with other chronic respiratory diseases is also recognised increasingly.…”

Section: Key Updatesmentioning

confidence: 99%

Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines

Chang

Bell²,

Torzillo

et al. 2015

Medical Journal of Australia

160

247

View full text Add to dashboard Cite

Section: Key Updatesmentioning

confidence: 99%

Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines

Chang

Bell²,

Torzillo

et al. 2015

Medical Journal of Australia

160

247

View full text Add to dashboard Cite

“…Little is known about the real risk factors that could lead to hospitalization. The study by Ringshausen et al 21 and Menéndez et al 2 reported that the average annual hospitalizations in the United States was 16.5 admissions per 100,000 inhabitants, while in Germany this value 9.4. In our study, there were 9 (9%) hospitalizations during the follow-up.…”

Section: Discussionmentioning

confidence: 97%

Follow-up of a cohort of patients with non-cystic fibrosis bronchiectasis for 1 year

Reb

Costa

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Non-cystic fibrosis bronchiectasis (NCFB) leads to progressive damage that may limit a patient’s daily activities and modify his/her quality of life. Our objective was to evaluate the quality of life of patients with bronchiectasis during a 1 year follow-up using the EQ-5D-3L questionnaire. Methods: A total of 100 patients with NCFB were recruited and followed-up with face-to-face visits or by telephone contact every three months for 1 year. At the time of recruiting and at the end of 1 year, the EQ-5D-3L questionnaire was applied to evaluate the patients’ quality of life. Variables, such as exacerbation, emergency care, comorbidities, hemoptysis, colonization, and hospitalization were assessed. Results: Of the 100 patients, 99 patients completed the study and 72% were women. There were no marked limitations in the mobility and self-care domains during the follow-up. Thirty-two patients were extremely anxious or depressed at the end of the follow-up. The quality of life assessed using EQ-5D-3L had an initial mean score of 0.545 and of 0.589 after 1 year, which was statistically significant (p= 0.011). Conclusion: Patients with NCFB have a poor quality of life and the EQ-5D-3L questionnaire may be a tool for monitoring patients with bronchiectasis.

show abstract

“…Despite the lack of epidemiological data in Korea, epidemiological studies have demonstrated that bronchiectasis poses a significant burden on public health, including increased healthcare costs, hospital admission and mortality 20–22. Therefore, we conducted a nationwide database study on the prevalence of bronchiectasis in Korea 6.…”

Section: Discussionmentioning

confidence: 99%

KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea

et al. 2020

View full text Add to dashboard Cite

IntroductionDespite the significant disease burden of bronchiectasis in Korea, no large-scale, representative prospective cohort studies have been conducted to evaluate the clinical characteristics of Korean patients with bronchiectasis, indicating an urgent need for cohort studies on bronchiectasis.Methods and analysisThe Korean Multicenter Bronchiectasis Audit and Research Collaboration (KMBARC) is a prospective, non-interventional observational cohort study on bronchiectasis in Korea. The inclusion criteria of this registry are as follows: (1) adult patients (aged ≥18 years) with or without respiratory symptoms (cough, chronic sputum and/or recurrent respiratory infection) and chest computed tomography revealing bronchiectasis affecting one or more lobes and (2) stable status at the time of registration: patients with bronchiectasis who were admitted for a respiratory aetiology can be enrolled at least 4 weeks after hospital discharge. The exclusion criteria are as follows: (1) bronchiectasis due to cystic fibrosis; (2) traction bronchiectasis associated with interstitial lung disease; (3) patients actively being treated for pneumonia, pulmonary tuberculosis or non-tuberculous mycobacterial infection; (4) patients who are unable or unwilling to provide informed consent; and (5) pregnant patients. Although the KMBARC questionnaires for baseline and annual follow-up data are similar to the European Multicentre Bronchiectasis Audit and Research Collaboration questionnaires, KMBARC has distinctive features such as use of Bronchiectasis Health Questionnaires, measurement with fatigue and depression scales, blood tests, use of consensus definition of exacerbations and information on emergency room or hospitalisation.We aim to recruit at least 1200 patients over the study period from more than 26 hospitals in South Korea. Patients will undergo a detailed baseline and yearly assessment for up to 5 years. The study objectives of the KMBARC registry are as follows: (1) uncovering the natural course of bronchiectasis; (2) aiding in establishing evidence-based bronchiectasis guidelines in Korea; and (3) encouraging and facilitating studies on bronchiectasis in Korea.Ethics and disseminationThis study received necessary approval from the Institutional Review Boards of all participating institutions. The Asan Medical Center Institutional Review Board gave overall approval for the study. Results will be disseminated via peer-reviewed publications and conference presentations.Trial registration numberKCT0003088.

show abstract

Bronchiectasis-Associated Hospitalizations in Germany, 2005 – 2011: A Population-Based Study of Disease Burden and Trends

Cited by 18 publications

References 0 publications

Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines

Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines

Follow-up of a cohort of patients with non-cystic fibrosis bronchiectasis for 1 year

KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea

Contact Info

Product

Resources

About